

As Introduced

**134th General Assembly
Regular Session
2021-2022**

H. C. R. No. 34

Representative Stewart

**Cosponsors: Representatives Bird, White, Russo, Plummer, John, Hall, Lampton,
Johnson, Cross, Baldrige**

A CONCURRENT RESOLUTION

To urge the Ohio delegation of the United States Congress 1
to investigate and prevent conflicts of interest 2
between federal agencies and the consulting firm 3
McKinsey & Company. 4

**BE IT RESOLVED BY THE HOUSE OF REPRESENTATIVES OF THE STATE OF
OHIO (THE SENATE CONCURRING):**

WHEREAS, Ohio has been greatly harmed by the distribution 5
of opioid drugs throughout the state, resulting in widespread 6
addiction among many Ohio residents and more than 23,000 opioid- 7
related overdose deaths from 2010-2019; and 8

WHEREAS, McKinsey & Company, a multi-billion dollar 9
consulting firm, devised strategies for its pharmaceutical 10
clients to, in its own words, "turbocharge" sales of OxyContin 11
pills into our state and therefore boost corporate profits; and 12

WHEREAS, A substantial portion of all opioid pills sold in 13
the United States of America from 2006-2014 can be traced to the 14
McKinsey & Company's consulting advice to its pharmaceutical 15
clients; and 16

WHEREAS, The State of Ohio joined 47 other states in 17
bringing a lawsuit against McKinsey & Company, resulting in a 18

settlement requiring the company to pay nearly \$600 million in 19
connection with its role in this crisis; and 20

WHEREAS, It has recently been discovered that McKinsey & 21
Company profited from a federal contract to provide consulting 22
services to the United States Food and Drug Administration 23
(FDA), during which it advised the FDA to streamline the 24
approval process for new medications – including opioids – while 25
McKinsey & Company was simultaneously under contract with the 26
firm's pharmaceutical clients to advise them on how to 27
circumvent the FDA's review; and 28

WHEREAS, This simultaneous arrangement between McKinsey & 29
Company, the FDA, and the company's pharmaceutical clients 30
constitutes a significant, undisclosed conflict of interest; and 31

WHEREAS, McKinsey has received, and continues to pursue, 32
lucrative federal contracts with the FDA and other federal 33
agencies; now therefore be it 34

RESOLVED, That we, the members of the 134th General 35
Assembly of the State of Ohio, in adopting this resolution, urge 36
Ohio's entire delegation in the United States Congress to 37
investigate and provide oversight with regard to McKinsey & 38
Company's role in perpetuating the distribution of opioid drugs 39
in Ohio and to take action to prevent conflicts of interest in 40
federal contracting with regard to McKinsey & Company, the FDA, 41
the Department of Defense, the Department of Veterans Affairs, 42
and other federal agencies; and be it further 43

RESOLVED, That the Clerk of the House of Representatives 44
transmit duly authenticated copies of this resolution to the 45
President of the United States Senate, the Speaker of the United 46
States House of Representatives, the members of the Ohio 47
congressional delegation, and the news media of Ohio. 48